Ashesh Das
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ashesh Das has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Harshawardhan Dhanraj Ramteke
Anhui Medical University
4 shared publications - Rakhshanda Khan
Ayaan Institute Of Medical Sciences, Hyderabad, India
4 shared publications - Bharadwaj Jilakaraju
Archbold medical center, USA
2 shared publications - Keerthi Sanapala
Andhra Medical College Vishakapatnam
2 shared publications - Sonam Dhall
DMCH Ludhiana, India
2 shared publications Aamuktha Marepalli
Sri Padmavathi Medical College for Women, Tirupati, India
1 shared publication
Latest Publications
- 31 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 917
Robotic-assisted endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a bayesian meta-analysis & systematic review
- 31 August 2026
- Published by Springer Nature in Journal of Robotic Surgery
- Vol. 20 (1) , 917
Robotic-assisted endoscopic submucosal dissection for superficial gastrointestinal neoplasms: a bayesian meta-analysis & systematic review
- 25 July 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- p. 1-12
Early versus delayed oral anticoagulation initiation after transcatheter aortic valve replacement in patients with atrial fibrillation: a retrospective cohort study
The optimal timing of oral anticoagulation (OAC) initiation after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation remains uncertain. This study compared early (within 2 days) versus delayed (5–7 days) OAC initiation on clinical outcomes in this population. In this retrospective cohort study using the TriNetX US Collaborative Network (data through 2024), we identified patients aged ≥ 18 years with atrial fibrillation or flutter undergoing TAVR via percutaneous femoral approach. Patients were categorized by OAC initiation timing post-TAVR. The index date was the TAVR procedure day; outcomes were assessed at 30 days, 90 days, and 1 year. Analyses used risk ratios (RRs), hazard ratios (HRs), Kaplan–Meier curves, and log-rank tests. After 1:1 propensity score matching, 3,372 patients remained in each cohort. Early OAC was associated with lower net adverse clinical events (NACE; all-cause mortality, stroke, arterial embolism or thrombosis, or major hemorrhage including transfusion) at 30 days (RR 0.754, 95% CI 0.683–0.832, p < 0.001), 90 days (RR 0.780, 95% CI 0.719–0.846, p < 0.001), and 1 year (RR 0.839, 95% CI 0.789–0.893, p < 0.001). All-cause mortality, major hemorrhage, and acute kidney injury were also significantly reduced with early OAC across all time points. Corresponding hazard ratios confirmed sustained benefit (30-day NACE HR 0.74, 95% CI 0.66–0.82; 1-year HR 0.79, 95% CI 0.73–0.85). Early OAC initiation within 2 days after TAVR was associated with lower NACE, mortality, hemorrhage, and acute kidney injury compared with initiation at 5–7 days in patients with atrial fibrillation. Prospective trials are warranted to confirm these findings. Graphical abstract
- 25 July 2026
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- p. 1-12
Early versus delayed oral anticoagulation initiation after transcatheter aortic valve replacement in patients with atrial fibrillation: a retrospective cohort study
The optimal timing of oral anticoagulation (OAC) initiation after transcatheter aortic valve replacement (TAVR) in patients with atrial fibrillation remains uncertain. This study compared early (within 2 days) versus delayed (5–7 days) OAC initiation on clinical outcomes in this population. In this retrospective cohort study using the TriNetX US Collaborative Network (data through 2024), we identified patients aged ≥ 18 years with atrial fibrillation or flutter undergoing TAVR via percutaneous femoral approach. Patients were categorized by OAC initiation timing post-TAVR. The index date was the TAVR procedure day; outcomes were assessed at 30 days, 90 days, and 1 year. Analyses used risk ratios (RRs), hazard ratios (HRs), Kaplan–Meier curves, and log-rank tests. After 1:1 propensity score matching, 3,372 patients remained in each cohort. Early OAC was associated with lower net adverse clinical events (NACE; all-cause mortality, stroke, arterial embolism or thrombosis, or major hemorrhage including transfusion) at 30 days (RR 0.754, 95% CI 0.683–0.832, p < 0.001), 90 days (RR 0.780, 95% CI 0.719–0.846, p < 0.001), and 1 year (RR 0.839, 95% CI 0.789–0.893, p < 0.001). All-cause mortality, major hemorrhage, and acute kidney injury were also significantly reduced with early OAC across all time points. Corresponding hazard ratios confirmed sustained benefit (30-day NACE HR 0.74, 95% CI 0.66–0.82; 1-year HR 0.79, 95% CI 0.73–0.85). Early OAC initiation within 2 days after TAVR was associated with lower NACE, mortality, hemorrhage, and acute kidney injury compared with initiation at 5–7 days in patients with atrial fibrillation. Prospective trials are warranted to confirm these findings. Graphical abstract
- Open Access
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4477
Dose–Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression
Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.
- 9 June 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (12) , 4477
Open AccessDose–Response Relationships and Comparative Efficacy of Aldosterone Synthase Inhibitors in Resistant Hypertension: A Comprehensive Network Meta-Analysis and Meta-Regression
Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.
- Open Access
Peroral Endoscopic Myotomy Versus Laparoscopic Heller Myotomy for Achalasia: A Meta-Analysis of Randomized Controlled Trials
Introduction: Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter relaxation and dysphagia. Laparoscopic Heller myotomy (LHM) has long been the standard treatment, while peroral endoscopic myotomy (POEM) has emerged as a minimally invasive alternative. Comparative evidence from randomized controlled trials (RCTs) remains limited, and outcomes such as gastroesophageal reflux disease (GERD) and clinical remission require clarification. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science to September 2025 for RCTs comparing POEM and LHM in adult patients with achalasia. Data on demographics, previous treatment, dysphagia improvement, GERD incidence, clinical remission, and mortality were extracted. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model in Stata 18. Results: Seven RCTs involving 900 patients (465 POEM; 465 LHM) were included. Dysphagia improvement was similar between groups (log OR 0.14; 95% CI −0.32 to 0.59; p = 0.55). GERD incidence was higher after POEM but not statistically significant (log OR 0.59; 95% CI −0.08 to 1.25; p = 0.08). Clinical remission showed a non-significant trend favoring POEM (log OR 0.39; 95% CI −0.06 to 0.84; p = 0.09). Reduction in pH levels significantly favored LHM (log OR 0.75; 95% CI 0.18 to 1.33; p = 0.01). No mortality was reported. Conclusion: POEM and LHM provide comparable dysphagia relief and clinical remission in achalasia. However, POEM is associated with higher GERD risk, particularly on pH monitoring. Treatment choice should balance efficacy against reflux risk, with careful long-term follow-up.
Open AccessPeroral Endoscopic Myotomy Versus Laparoscopic Heller Myotomy for Achalasia: A Meta-Analysis of Randomized Controlled Trials
Introduction: Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter relaxation and dysphagia. Laparoscopic Heller myotomy (LHM) has long been the standard treatment, while peroral endoscopic myotomy (POEM) has emerged as a minimally invasive alternative. Comparative evidence from randomized controlled trials (RCTs) remains limited, and outcomes such as gastroesophageal reflux disease (GERD) and clinical remission require clarification. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science to September 2025 for RCTs comparing POEM and LHM in adult patients with achalasia. Data on demographics, previous treatment, dysphagia improvement, GERD incidence, clinical remission, and mortality were extracted. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model in Stata 18. Results: Seven RCTs involving 900 patients (465 POEM; 465 LHM) were included. Dysphagia improvement was similar between groups (log OR 0.14; 95% CI −0.32 to 0.59; p = 0.55). GERD incidence was higher after POEM but not statistically significant (log OR 0.59; 95% CI −0.08 to 1.25; p = 0.08). Clinical remission showed a non-significant trend favoring POEM (log OR 0.39; 95% CI −0.06 to 0.84; p = 0.09). Reduction in pH levels significantly favored LHM (log OR 0.75; 95% CI 0.18 to 1.33; p = 0.01). No mortality was reported. Conclusion: POEM and LHM provide comparable dysphagia relief and clinical remission in achalasia. However, POEM is associated with higher GERD risk, particularly on pH monitoring. Treatment choice should balance efficacy against reflux risk, with careful long-term follow-up.
- Open Access
Biologics for Eosinophilic Oesophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated disease characterized by oesophageal dysfunction and mucosal eosinophilia. Conventional therapies, including dietary elimination, proton pump inhibitors, and topical corticosteroids, are often insufficient or associated with relapse, highlighting the need for targeted treatments. Biologic agents modulating type 2 inflammation have emerged as promising options. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of biologics in EoE. Methods: Electronic databases (PubMed, Embase, CENTRAL, Web of Science, Scopus) and trial registries were searched from inception to [insert date]. Eligible studies were double-blind RCTs comparing biologics with placebo in EoE. Data extraction and risk-of-bias assessment (RoB 2.0) were performed independently by two reviewers. Pooled analyses were conducted using random-effects models, reporting log odds ratios (OR) or risk ratios (RR) with 95% confidence intervals (CIs). Certainty of evidence was rated with GRADE. Results: A total of 1,706 patients (1,046 males and 696 females; mean age 56.1±15 years; mean follow-up 9.2 months) from 14 randomized controlled trials were included, with 982 patients receiving biologics and 723 assigned to placebo. Biologics significantly increased histological remission compared with placebo (log OR 1.57, 95% CI 0.55-2.60; I2 = 89.6%), with benralizumab and lirentelimab demonstrating the strongest effects, while dupilumab showed variable histological outcomes but consistent symptomatic benefits in pivotal trials. Symptomatic response did not improve significantly overall (log OR 0.18, 95% CI −0.73-1.09), although benralizumab showed benefit and lirentelimab trended negatively. Endoscopic remission was not significantly different between biologics and placebo (log OR −0.38, 95% CI −1.56-0.79). Safety analyses revealed no overall increase in adverse events (log RR −0.10, 95% CI −0.40-0.19), with etarsimod and reslizumab associated with fewer events, while lirentelimab suggested a possible increase in cardiological adverse events. Neurological adverse events were infrequent and comparable to placebo. Conclusion Biologic therapies are effective in achieving histological remission in EoE, with benralizumab, lirentelimab, and dupilumab showing the greatest promise. Symptomatic and endoscopic benefits are less consistent, underscoring the need for standardized outcome measures. Biologics were generally safe, with no overall increase in adverse events. These findings support the expanding role of biologics in EoE management while highlighting the importance of long-term and head-to-head trials to optimize therapeutic strategies.
Open AccessBiologics for Eosinophilic Oesophagitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Introduction: Eosinophilic oesophagitis (EoE) is a chronic, immune-mediated disease characterized by oesophageal dysfunction and mucosal eosinophilia. Conventional therapies, including dietary elimination, proton pump inhibitors, and topical corticosteroids, are often insufficient or associated with relapse, highlighting the need for targeted treatments. Biologic agents modulating type 2 inflammation have emerged as promising options. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) to evaluate the efficacy and safety of biologics in EoE. Methods: Electronic databases (PubMed, Embase, CENTRAL, Web of Science, Scopus) and trial registries were searched from inception to [insert date]. Eligible studies were double-blind RCTs comparing biologics with placebo in EoE. Data extraction and risk-of-bias assessment (RoB 2.0) were performed independently by two reviewers. Pooled analyses were conducted using random-effects models, reporting log odds ratios (OR) or risk ratios (RR) with 95% confidence intervals (CIs). Certainty of evidence was rated with GRADE. Results: A total of 1,706 patients (1,046 males and 696 females; mean age 56.1±15 years; mean follow-up 9.2 months) from 14 randomized controlled trials were included, with 982 patients receiving biologics and 723 assigned to placebo. Biologics significantly increased histological remission compared with placebo (log OR 1.57, 95% CI 0.55-2.60; I2 = 89.6%), with benralizumab and lirentelimab demonstrating the strongest effects, while dupilumab showed variable histological outcomes but consistent symptomatic benefits in pivotal trials. Symptomatic response did not improve significantly overall (log OR 0.18, 95% CI −0.73-1.09), although benralizumab showed benefit and lirentelimab trended negatively. Endoscopic remission was not significantly different between biologics and placebo (log OR −0.38, 95% CI −1.56-0.79). Safety analyses revealed no overall increase in adverse events (log RR −0.10, 95% CI −0.40-0.19), with etarsimod and reslizumab associated with fewer events, while lirentelimab suggested a possible increase in cardiological adverse events. Neurological adverse events were infrequent and comparable to placebo. Conclusion Biologic therapies are effective in achieving histological remission in EoE, with benralizumab, lirentelimab, and dupilumab showing the greatest promise. Symptomatic and endoscopic benefits are less consistent, underscoring the need for standardized outcome measures. Biologics were generally safe, with no overall increase in adverse events. These findings support the expanding role of biologics in EoE management while highlighting the importance of long-term and head-to-head trials to optimize therapeutic strategies.
- Open Access
Comparative Efficacy and Safety of Soluble Guanylate Cyclase Stimulators in Heart Failure with Preserved Ejection Fraction: A Network Meta-Analysis
Background: Heart failure with preserved ejection fraction (HFpEF) makes up nearly half of all heart failure cases and remains a difficult condition to treat due to limited therapeutic options. Soluble guanylate cyclase (sGC) stimulators—namely Riociguat, Vericiguat, and Praliciguat—have shown potential in improving heart muscle relaxation and vascular function. However, their comparative effectiveness and safety are still uncertain. Methods: We conducted a Bayesian network meta-analysis (NMA) that included eight randomized controlled trials encompassing 7,330 HFpEF patients, with an average age of 69.5 years. The outcomes evaluated included survival rates, left ventricular ejection fraction (LVEF), NT-proBNP levels, hospital readmissions, New York Heart Association (NYHA) functional class, and adverse events. Treatment outcomes were presented as odds ratios (OR) or mean differences (MD) along with 95% credible intervals (CrI). Results: Riociguat indicated a potentially favourable survival benefit (OR 3.69, 95% CrI: 0.53–29.2) and a reduced risk of hospital readmission (OR 0.40, 0.11–1.30), though these findings were not definitive. Praliciguat had neutral effects on survival (OR 1.05, 0.017–61.0). Vericiguat did not improve survival (OR 0.42, 0.12–1.16) but did offer a modest improvement in NYHA functional class (log RR 0.27, –0.12 to 0.67). Changes in LVEF were unclear: Riociguat (MD 3.00, –1.15 to 7.13), Vericiguat (MD 1.59, –2.03 to 5.17), and Praliciguat (MD –0.19, – 7.34 to 6.84). Riociguat was associated with a reduction in NT-proBNP levels (MD –7.41, –21.2 to 4.41), whereas Vericiguat (0.65, –9.54 to 10.8) and Praliciguat (5.28, –12.6 to 23.0) had neutral effects. Adverse events such as headache (log RR 0.21, –0.35 to 0.78), low blood pressure (0.42, –0.21 to 1.05), and neurological symptoms (–0.04, –0.87 to 0.79) were not significantly increased. Conclusion: Among the agents studied, Riociguat showed the most promise in terms of survival and reducing hospital readmissions in HFpEF patients. Vericiguat offered modest improvements in patient functional status, while Praliciguat had minimal clinical impact. The findings suggest that more extensive, long-term clinical trials are needed to better establish the efficacy and safety of these therapies.
Open AccessComparative Efficacy and Safety of Soluble Guanylate Cyclase Stimulators in Heart Failure with Preserved Ejection Fraction: A Network Meta-Analysis
Background: Heart failure with preserved ejection fraction (HFpEF) makes up nearly half of all heart failure cases and remains a difficult condition to treat due to limited therapeutic options. Soluble guanylate cyclase (sGC) stimulators—namely Riociguat, Vericiguat, and Praliciguat—have shown potential in improving heart muscle relaxation and vascular function. However, their comparative effectiveness and safety are still uncertain. Methods: We conducted a Bayesian network meta-analysis (NMA) that included eight randomized controlled trials encompassing 7,330 HFpEF patients, with an average age of 69.5 years. The outcomes evaluated included survival rates, left ventricular ejection fraction (LVEF), NT-proBNP levels, hospital readmissions, New York Heart Association (NYHA) functional class, and adverse events. Treatment outcomes were presented as odds ratios (OR) or mean differences (MD) along with 95% credible intervals (CrI). Results: Riociguat indicated a potentially favourable survival benefit (OR 3.69, 95% CrI: 0.53–29.2) and a reduced risk of hospital readmission (OR 0.40, 0.11–1.30), though these findings were not definitive. Praliciguat had neutral effects on survival (OR 1.05, 0.017–61.0). Vericiguat did not improve survival (OR 0.42, 0.12–1.16) but did offer a modest improvement in NYHA functional class (log RR 0.27, –0.12 to 0.67). Changes in LVEF were unclear: Riociguat (MD 3.00, –1.15 to 7.13), Vericiguat (MD 1.59, –2.03 to 5.17), and Praliciguat (MD –0.19, – 7.34 to 6.84). Riociguat was associated with a reduction in NT-proBNP levels (MD –7.41, –21.2 to 4.41), whereas Vericiguat (0.65, –9.54 to 10.8) and Praliciguat (5.28, –12.6 to 23.0) had neutral effects. Adverse events such as headache (log RR 0.21, –0.35 to 0.78), low blood pressure (0.42, –0.21 to 1.05), and neurological symptoms (–0.04, –0.87 to 0.79) were not significantly increased. Conclusion: Among the agents studied, Riociguat showed the most promise in terms of survival and reducing hospital readmissions in HFpEF patients. Vericiguat offered modest improvements in patient functional status, while Praliciguat had minimal clinical impact. The findings suggest that more extensive, long-term clinical trials are needed to better establish the efficacy and safety of these therapies.
- Open Access
Comparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysis
Introduction: Cushing’s disease (CD) is a rare endocrine disorder characterized by excessive cortisol production due to a pituitary adenoma secreting ACTH, leading to a range of systemic effects including obesity, hypertension, and hyperglycemia. The condition is often underdiagnosed, with an incidence of 2-3 cases per million people annually. While surgery remains the first-line treatment, adjunctive medical therapies are essential for non-surgical candidates or those with recurrent disease. This systematic review and network meta-analysis (NMA) evaluate the comparative efficacy and safety of medical treatments for Cushing’s disease. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and observational studies published between 2010 and 2023. Studies were included if they assessed the efficacy and/or safety of medical treatments for Cushing’s disease. Data extraction was performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs and ROBS 2.0 for observational studies. Network meta-analysis was performed using a random-effects model to compare treatments across different outcomes. Results: A total of 29 studies involving 1,736 patients were included in the analysis. The patient cohort comprised 600 males (34.5%) and 1,132 females (65.5%), with an average age of 41.09 years. Among the treatments, 960 patients (55.3%) received Pasireotide, 143 (8.2%) Osilodrostat, 126 (7.3%) Mifepristone, and 176 (10.1%) Levoketoconazole. In terms of 24-hour urinary free cortisol (UFC) reduction, Levoketoconazole showed a mean difference of -329 (95% CI: -2.33e+03, 1.70e+03), Mifepristone -381 (95% CI: -3.27e+03, 1.74e+03), Osilodrostat -214 (95% CI: -1.60e+03, 1.25e+03), and Pasireotide -331 (95% CI: -1.75e+03, 1.09e+03). Despite all treatments reducing UFC levels, the broad confidence intervals suggest substantial uncertainty in the efficacy estimates. Regarding the change in cortisol levels, Mifepristone showed a mean difference of 290 (95% CI: -285, 888), Osilodrostat 15.6 (95% CI: -806, 835), and Pasireotide -6.17 (95% CI: -821, 815), indicating considerable variability in treatment effects. The analysis of ACTH levels revealed similar trends, with Levoketoconazole and Mifepristone showing more pronounced reductions compared to Osilodrostat. In terms of overall survival, Levoketoconazole demonstrated a survival rate of 0.82 (95% CI: 0.72–0.91), while Mifepristone had a pooled survival rate of 0.94 (95% CI: 0.86–1.02). The analysis of disease-free survival indicated an overall pooled survival rate of 0.80 (95% CI: 0.70–0.90). Quality of life (QOL) improvements were variable, with Osilodrostat showing a mean difference of -11.72 (95% CI: -18.32, -5.12). There were no significant differences in the risk of gastrointestinal, cardiovascular, or neurological adverse events between treatments. Conclusion: This systematic review and network meta-analysis provide valuable insights into the comparative efficacy and safety of medical treatments for Cushing’s disease. While Pasireotide and Levoketoconazole consistently reduce UFC levels, Mifepristone and Osilodrostat also show potential, albeit with greater variability in clinical outcomes. The high heterogeneity observed across studies suggests the need for further research to refine treatment strategies and optimize patient management. Personalized treatment approaches, incorporating both efficacy and safety considerations, will be crucial for improving outcomes and minimizing the burden of this disease.
Open AccessComparative Efficacy and Safety of Medical Treatments for Cushing’s Disease: A Systematic Review and Network Meta-Analysis
Introduction: Cushing’s disease (CD) is a rare endocrine disorder characterized by excessive cortisol production due to a pituitary adenoma secreting ACTH, leading to a range of systemic effects including obesity, hypertension, and hyperglycemia. The condition is often underdiagnosed, with an incidence of 2-3 cases per million people annually. While surgery remains the first-line treatment, adjunctive medical therapies are essential for non-surgical candidates or those with recurrent disease. This systematic review and network meta-analysis (NMA) evaluate the comparative efficacy and safety of medical treatments for Cushing’s disease. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and observational studies published between 2010 and 2023. Studies were included if they assessed the efficacy and/or safety of medical treatments for Cushing’s disease. Data extraction was performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs and ROBS 2.0 for observational studies. Network meta-analysis was performed using a random-effects model to compare treatments across different outcomes. Results: A total of 29 studies involving 1,736 patients were included in the analysis. The patient cohort comprised 600 males (34.5%) and 1,132 females (65.5%), with an average age of 41.09 years. Among the treatments, 960 patients (55.3%) received Pasireotide, 143 (8.2%) Osilodrostat, 126 (7.3%) Mifepristone, and 176 (10.1%) Levoketoconazole. In terms of 24-hour urinary free cortisol (UFC) reduction, Levoketoconazole showed a mean difference of -329 (95% CI: -2.33e+03, 1.70e+03), Mifepristone -381 (95% CI: -3.27e+03, 1.74e+03), Osilodrostat -214 (95% CI: -1.60e+03, 1.25e+03), and Pasireotide -331 (95% CI: -1.75e+03, 1.09e+03). Despite all treatments reducing UFC levels, the broad confidence intervals suggest substantial uncertainty in the efficacy estimates. Regarding the change in cortisol levels, Mifepristone showed a mean difference of 290 (95% CI: -285, 888), Osilodrostat 15.6 (95% CI: -806, 835), and Pasireotide -6.17 (95% CI: -821, 815), indicating considerable variability in treatment effects. The analysis of ACTH levels revealed similar trends, with Levoketoconazole and Mifepristone showing more pronounced reductions compared to Osilodrostat. In terms of overall survival, Levoketoconazole demonstrated a survival rate of 0.82 (95% CI: 0.72–0.91), while Mifepristone had a pooled survival rate of 0.94 (95% CI: 0.86–1.02). The analysis of disease-free survival indicated an overall pooled survival rate of 0.80 (95% CI: 0.70–0.90). Quality of life (QOL) improvements were variable, with Osilodrostat showing a mean difference of -11.72 (95% CI: -18.32, -5.12). There were no significant differences in the risk of gastrointestinal, cardiovascular, or neurological adverse events between treatments. Conclusion: This systematic review and network meta-analysis provide valuable insights into the comparative efficacy and safety of medical treatments for Cushing’s disease. While Pasireotide and Levoketoconazole consistently reduce UFC levels, Mifepristone and Osilodrostat also show potential, albeit with greater variability in clinical outcomes. The high heterogeneity observed across studies suggests the need for further research to refine treatment strategies and optimize patient management. Personalized treatment approaches, incorporating both efficacy and safety considerations, will be crucial for improving outcomes and minimizing the burden of this disease.